ToleroGenics

ToleroGenics is an early-stage biotechnology company pioneering a curative approach to immune-mediated diseases through its proprietary tolerance-inducing platform. Its core technology combines thermosensitive hydrogels for sustained drug delivery with specialized adjuvants like PLGA nanoparticles and phosphatidylserine (PS)-liposomes to reprogram dendritic cells and boost regulatory T cells (Tregs). The company is seeking investment to advance its pipeline, aiming to overcome the limitations of current allergen-specific immunotherapies (AIT) by offering safer, more effective, and shorter-duration treatments.

A proprietary platform combining a thermosensitive hydrogel (ImmunoGel) for sustained subcutaneous delivery with multiple adjuvant technologies (ToleroSphere, PhagoAttract, ToleroPrime) designed to recruit antigen-presenting cells, convert them to a tolerogenic state, and promote antigen-specific regulatory T cell expansion to induce immune tolerance.

ToleroGenics competes in the tolerance-inducing immunotherapy space, which includes companies developing antigen-specific therapies (e.g., peptide immunotherapy, Treg cell therapies) and broader immune-modulators. It differentiates itself with its localized, combination delivery platform designed for safety and short treatment duration. Key competitors range from established AIT product companies (e.g., ALK, Stallergenes Greer) to biotechs exploring novel tolerance mechanisms.